Skip to main content
NCBI home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
. 2012 Jul 21;2(2):200–205. doi: 10.1016/S0973-6883(12)60115-7

Answers to Multiple Choice Questions

Swastik Agrawal 1, Radha K Dhiman 1
PMCID: PMC3940322  PMID: 25755434

Full Text

The Full Text of this article is available as a PDF (138.8 KB).

References

  • 1.Werle-Lapostolle B, Bowden S, Lacorini S. Persistence of cccDNA during natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758. doi: 10.1053/j.gastro.2004.03.018. [DOI] [PubMed] [Google Scholar]
  • 2.Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010;52:475–477. doi: 10.1016/j.jhep.2009.12.020. [DOI] [PubMed] [Google Scholar]
  • 3.Seth AK. HBsAg quantification in clinical practice. J Clin Exp Hepatol. 2012;2:75–80. doi: 10.1016/S0973-6883(12)60084-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Brunetto MR, Oliveri F, Colombatto P. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–490. doi: 10.1053/j.gastro.2010.04.052. [DOI] [PubMed] [Google Scholar]
  • 5.Martinot-Peignoux M, Lada O, Cardoso AC. Quantitative HBsAg: a new specific marker for diagnosis of HBsAg inactive carriage (Abstract) Hepatology. 2010;52:992A. [Google Scholar]
  • 6.Manesis EK, Papatheodoridis GV, Hadziyannis E. Significance of serum HBsAg levels for the definition of the inactive HBsAg carrier state (Abstract) Hepatology. 2010;52(Suppl):560A. [Google Scholar]
  • 7.Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323–1331. doi: 10.1111/j.1365-2036.2010.04474.x. [DOI] [PubMed] [Google Scholar]
  • 8.Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treat-ment hepatitis B surface antigen decline. Hepatology. 2010;52:1251–1257. doi: 10.1002/hep.23844. [DOI] [PubMed] [Google Scholar]
  • 9.Reinjnders JGP, Rijckborst V, Sonneveld MJ. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449–454. doi: 10.1016/j.jhep.2010.07.046. [DOI] [PubMed] [Google Scholar]
  • 10.Jung YK, Kim JH, Lee YS. Change in serum hepatitis B surface antigen level and its clinical significance in treatment naïve hepatitis B e-antigen positive patients receiving entecavir. J Clin Gastroenterol. 2010;44:653–657. doi: 10.1097/MCG.0b013e3181d52946. [DOI] [PubMed] [Google Scholar]
  • 11.Wursthorn K, Jung M, Riva A. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611–1620. doi: 10.1002/hep.23905. [DOI] [PubMed] [Google Scholar]
  • 12.Cai W, Xie Q, An B. On-treatment serum HBsAg level is predictive of sustained off-treatment virological response to telbividine in HBeAg-positive chronic hepatitis B patients. J Clin Virol. 2010;48:22–26. doi: 10.1016/j.jcv.2010.02.014. [DOI] [PubMed] [Google Scholar]
  • 13.Greif F, Bronsther OL, Van Thiel DH. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg. 1994;219:40–45. doi: 10.1097/00000658-199401000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after liver transplantation: a review. Dig Surg. 2008;25:245–257. doi: 10.1159/000144653. [DOI] [PubMed] [Google Scholar]
  • 15.Atwal T, Pastrana M, Sandhu M. Post-liver transplant biliary complications. J Clin Exp Hepatol. 2012;2:81–85. doi: 10.1016/S0973-6883(12)60085-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Moser MA, Wall WJ. Management of biliary problems after liver transplantation. Liver Trans. 2001;7:S46–S52. doi: 10.1053/jlts.2001.28518. [DOI] [PubMed] [Google Scholar]
  • 17.O'Connor TP, Lewis WD, Jenkins RL. Biliary tract complications after liver transplantation. Arch Surg. 1995;130:312–317. doi: 10.1001/archsurg.1995.01430030082017. [DOI] [PubMed] [Google Scholar]
  • 18.Graziadei IW, Schwaighofer H, Koch R. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl. 2006;12:718–725. doi: 10.1002/lt.20644. [DOI] [PubMed] [Google Scholar]
  • 19.Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol. 2012;2:42–54. doi: 10.1016/S0973-6883(12)60090-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2009:CD005527. doi: 10.1002/14651858.CD005527.pub2. [DOI] [PubMed] [Google Scholar]
  • 21.Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–924. doi: 10.1038/nature03153. [DOI] [PubMed] [Google Scholar]
  • 22.Hofmann WP, Chung TL, Osbahr C. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-a and the protease inhibitors boceprevir or telaprevir. Antivir Ther. 2011;16:695–704. doi: 10.3851/IMP1821. [DOI] [PubMed] [Google Scholar]
  • 23.Hézode C, Forestier N, Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850. doi: 10.1056/NEJMoa0807650. [DOI] [PubMed] [Google Scholar]
  • 24.McHutchison JG, Manns MP, Muir AJ. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–1303. doi: 10.1056/NEJMoa0908014. [DOI] [PubMed] [Google Scholar]
  • 25.Kwo PY, Lawitz EJ, McCone J. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. doi: 10.1016/S0140-6736(10)60934-8. [DOI] [PubMed] [Google Scholar]
  • 26.Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103:1981–1988. doi: 10.1111/j.1572-0241.2008.01957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hung CH, Lee CM, Lu SN. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int. 2006;26:1079–1086. doi: 10.1111/j.1478-3231.2006.01354.x. [DOI] [PubMed] [Google Scholar]
  • 28.Arase Y, Ikeda K, Tsubota A. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology. 2005;48:138–144. doi: 10.1159/000081741. [DOI] [PubMed] [Google Scholar]
  • 29.Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet. 2004;19:438–443. doi: 10.2133/dmpk.19.438. [DOI] [PubMed] [Google Scholar]
  • 30.Bhatia V. Endoscopic ultrasound (EUS) for esophageal and gastric varices: how can it improve the outcomes and reduce complications of glue injection. J Clin Exp Hepatol. 2012;2:70–74. doi: 10.1016/S0973-6883(12)60083-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992;16:1343–1349. doi: 10.1002/hep.1840160607. [DOI] [PubMed] [Google Scholar]
  • 32.Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K. Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology. 1988;95:434–440. doi: 10.1016/0016-5085(88)90501-x. [DOI] [PubMed] [Google Scholar]
  • 33.Saraswat VA, Verma A. Gluing gastric varices in 2012: lessons learnt over 25 years. J Clin Exp Hepatol. 2012;2:55–69. doi: 10.1016/S0973-6883(12)60088-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mishra SR, Sharma BC, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut. 2010;59:729–735. doi: 10.1136/gut.2009.192039. [DOI] [PubMed] [Google Scholar]
  • 35.Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol. 2011;54:1161–1167. doi: 10.1016/j.jhep.2010.09.031. [DOI] [PubMed] [Google Scholar]
  • 36.Pham TNQ, Michalak TI. Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol. 2011;1:185–189. doi: 10.1016/S0973-6883(11)60130-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ciancio A, Smedile A, Giordanino C. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol. 2006;101:1811–1816. doi: 10.1111/j.1572-0241.2006.00669.x. [DOI] [PubMed] [Google Scholar]
  • 38.Radkowski M, Gallegos-Orozco JF, Jablonska J. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106–114. doi: 10.1002/hep.20518. [DOI] [PubMed] [Google Scholar]
  • 39.Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat. 2012;19:103–111. doi: 10.1111/j.1365-2893.2011.01442.x. [DOI] [PubMed] [Google Scholar]
  • 40.Casato M, Lilli D, Donato G. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. J Viral Hepat. 2003;10:455–459. doi: 10.1046/j.1365-2893.2003.00462.x. [DOI] [PubMed] [Google Scholar]
  • 41.Pardo M, Castillo I, Arenas MD. Antiviral therapy in patients with occult HCV infection. Hepatology. 2005;42:658A. [Google Scholar]
  • 42.Murray KF, Carithers RL, Jr, AASLD AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–1432. doi: 10.1002/hep.20704. [DOI] [PubMed] [Google Scholar]
  • 43.Thuluvath PJ. Evaluation of liver transplant recipients. J Clin Exp Hepatol. 2011;1:199–203. doi: 10.1016/S0973-6883(11)60238-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Freeman RB, Jr, Gish RG, Harper A. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006;12(Suppl 3):S128–S136. doi: 10.1002/lt.20979. [DOI] [PubMed] [Google Scholar]
  • 45.Merli M, Giusto M, Giannelli V, Lucidi C, Riggio O. Nutritional status and liver transplantation. J Clin Exp Hepatol. 2011;1:190–198. doi: 10.1016/S0973-6883(11)60237-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Italian multicentric cooperative project on nutrition in liver cirrhosis. Nutritional status in cirrhosis. Italian multicentric cooperative project on nutrition in liver cirrhosis. J Hepatol. 1994;21:317–325. [PubMed] [Google Scholar]
  • 47.Caregaro L, Alberino F, Amodio P. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–609. doi: 10.1093/ajcn/63.4.602. [DOI] [PubMed] [Google Scholar]
  • 48.Alberino F, Gatta A, Amodio P. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–450. doi: 10.1016/s0899-9007(01)00521-4. [DOI] [PubMed] [Google Scholar]
  • 49.Gunsar F, Raimondo ML, Jones S. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563–572. doi: 10.1111/j.1365-2036.2006.03003.x. [DOI] [PubMed] [Google Scholar]
  • 50.Plauth M, Cabré E, Riggio O. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25:285–294. doi: 10.1016/j.clnu.2006.01.018. [DOI] [PubMed] [Google Scholar]
  • 51.Miwa Y, Shiraki M, Kato M. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatol Res. 2000;18:184–189. doi: 10.1016/s1386-6346(99)00100-x. [DOI] [PubMed] [Google Scholar]
  • 52.Yamauchi M, Takeda K, Sakamoto K, Ohata M, Toda G. Effect of oral branched chain amino acid supplementation in the late evening on the nutritional state of patients with liver cirrhosis. Hepatol Res. 2001;21:199–204. doi: 10.1016/s1386-6346(01)00105-x. [DOI] [PubMed] [Google Scholar]
  • 53.Dogra S, Jindal R. Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol. 2011;1:177–184. doi: 10.1016/S0973-6883(11)60235-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005–1013. doi: 10.1053/he.2000.5984. [DOI] [PubMed] [Google Scholar]
  • 55.Johnston GA, Graham Brown RAC. The skin and disorders of the alimentary tract, the hepatobiliary system, kidney, and cardiopulmonary system. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. McGraw Hill; New York: 2008. pp. 1445–1460. [Google Scholar]
  • 56.Anand AC, Mukherjee D, Rao KS, Seth AK. Hepatopulmonary syndrome: prevalence and clinical profile. Indian J Gastroenterol. 2001;20:24–27. [PubMed] [Google Scholar]
  • 57.Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol. 2006;18:54–63. doi: 10.1097/01.bor.0000198002.42826.c2. [DOI] [PubMed] [Google Scholar]
  • 58.Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374. doi: 10.1002/hep.22759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Atluri DK, Prakash R, Mullen KD. Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol. 2011;1:77–86. doi: 10.1016/S0973-6883(11)60126-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Bajaj JS, Cordoba J, Mullen KD. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33:739–747. doi: 10.1111/j.1365-2036.2011.04590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Cordoba J, Sanpedro F, Alonso J, Rovira A. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis. 2002;17:415–429. doi: 10.1023/a:1021926405944. [DOI] [PubMed] [Google Scholar]
  • 62.Rovira A, Alonso J, Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008;29:1612–1621. doi: 10.3174/ajnr.A1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 2008;14:3609–3615. doi: 10.3748/wjg.14.3609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549–559. doi: 10.1002/hep.21533. [DOI] [PubMed] [Google Scholar]
  • 65.Rajekar H, Vasishta RK, Chawla YK, Dhiman RK. Noncirrhotic portal hypertension. J Clin Exp Hepatol. 2011;1:94–108. doi: 10.1016/S0973-6883(11)60128-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Dhiman RK. Spectrum of idiopathic noncirrhotic portal hypertension. J Clin Exp Hepatol. 2011;1:55–56. doi: 10.1016/S0973-6883(11)60122-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Cazals-Hatem D, Hillaire S, Rudler M. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455–461. doi: 10.1016/j.jhep.2010.07.038. [DOI] [PubMed] [Google Scholar]
  • 68.Bernard PH, Le Bail B, Cransac M. Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol. 1995;22:495–499. doi: 10.1016/0168-8278(95)80115-4. [DOI] [PubMed] [Google Scholar]
  • 69.Saigal S, Nayak NC, Jain D. Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients. Hepatol Int. 2011 doi: 10.1007/s12072-010-9246-7. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  • 70.Sarin SK, Agarwal SR. Extrahepatic portal vein obstruction. Semin Liver Dis. 2002;22:43–58. doi: 10.1055/s-2002-23206. [DOI] [PubMed] [Google Scholar]
  • 71.Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56:1001–1008. doi: 10.1136/gut.2006.103606. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES